Followers | 35 |
Posts | 6308 |
Boards Moderated | 0 |
Alias Born | 02/09/2015 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, November 20, 2015 9:24:45 AM
In short, there are a lot of options and nothing has any great efficacy. The recommendations are for paclitaxel, and doxorubicin, and others, incl gemcitabine. Also if BRCA + then olaparib. Other therapies mentioned are an angiogennesis -umab(long to write out), hormonal therapies(letrozole etc)
Docetaxel is mentioned, along with its significant toxicites, esp hematologic and nausea and vomiting(of course dose related).
Presumably CTIX tested K with all of these drugs and came up with docetaxel as most efficacious? Much is made of side effects in terms of choice of agent as next drug, for example, in the discussion of PLD(Doxorubicin)- given infrequently, few side effects etc. Would be nice for the company to say more about its choice, since the article does not list Docetaxel as one of the first few options .
The side effect discussion is of course a distant second to efficacy if efficacy can be shown with K.
The article is discussing a group of patients who are in a difficult spot- not responding to typical platinum regimens, with a relentless cancer, so side effects have real relevance.
Kevetrin has a real opportunity here, since current therapy has bleak prospects, and K thus far little in the way of side effects.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM
Element79 Gold Corp Announces 2024 Clover Work Plans & Nevada Portfolio Updates • ELMGF • Sep 10, 2024 11:00 AM
Nightfood Holdings Inc. Completes Major Step on Uplist Journey by Closing Strategic All-Stock Acquisition of CarryoutSupplies.com • NGTF • Sep 10, 2024 8:15 AM
Element79 Gold Corp. Announces Sale of 100% Interest in Elder Creek, North Mill Creek, and Elephant Projects to 1472886 B.C. Ltd. • ELEM • Sep 9, 2024 9:34 AM